AT-7519 Uses, Dosage, Side Effects and more
AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.
| Attribute | Details |
|---|---|
| Trade Name | AT-7519 |
| Generic | AT-7519 |
| Type | |
| Formula | C16H17Cl2N5O2 |
| Weight | Average: 382.244 Monoisotopic: 381.075930227 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in leukemia (unspecified), lymphoma (unspecified), myelodysplastic syndrome, and solid tumors.
How AT-7519 works
AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression.
